Gene · 9436
Papers3,322
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,322
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis. | Pathogens | 2023 | 38133265 | PubTator, text mining | PubMed |
| ROS regulation in gliomas: implications for treatment strategies. | Front Immunol | 2023 | 38130720 | PubTator, text mining | PubMed |
| g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral blood. | Oncoimmunology | 2023 | 38126036 | PubTator, text mining | PubMed |
| Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation. | Hepatobiliary Surg Nutr | 2023 | 38115918 | PubTator, text mining | PubMed |
| A distinct human cell type expressing MHCII and RORγt with dual characteristics of dendritic cells and type 3 innate lymphoid cells. | Proc Natl Acad Sci U S A | 2023 | 38109523 | PubTator, text mining | PubMed |
| Mapping the protein-protein interactome in the tumor immune microenvironment. | Antib Ther | 2023 | 38098892 | PubTator, text mining | PubMed |
| Role of the immune system in liver transplantation and its implications for therapeutic interventions. | MedComm (2020) | 2023 | 38098611 | PubTator, text mining | PubMed |
| Killer instincts: natural killer cells as multifactorial cancer immunotherapy. | Front Immunol | 2023 | 38090565 | PubTator, text mining | PubMed |
| Sex and gender affect immune aging. | Front Aging | 2023 | 38088954 | PubTator, text mining | PubMed |
| Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. | J Immunother Cancer | 2023 | 38081778 | PubTator, text mining | PubMed |
| Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. | Front Immunol | 2023 | 38077402 | PubTator, text mining | PubMed |
| Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. | Front Immunol | 2023 | 38077389 | PubTator, text mining | PubMed |
| CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects. | Cells | 2023 | 38067178 | PubTator, text mining | PubMed |
| NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment. | Cells | 2023 | 38067177 | PubTator, text mining | PubMed |
| The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. | Cancer Cell Int | 2023 | 38057843 | PubTator, text mining | PubMed |
| Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer. | J Immunother Cancer | 2023 | 38056896 | PubTator, text mining | PubMed |
| Senescence-associated secretory phenotypes in mesenchymal cells contribute to cytotoxic immune response in oral lichen planus. | Immun Ageing | 2023 | 38053160 | PubTator, text mining | PubMed |
| Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy. | MedComm (2020) | 2023 | 38045827 | PubTator, text mining | PubMed |
| Deficiency of N-linked glycosylation impairs immune function of B7-H6. | Front Immunol | 2023 | 38035117 | PubTator, text mining | PubMed |
| Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy. | Front Immunol | 2023 | 38035069 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9436/papers?page=8